Krystal Biotech (KRYS) Convertible Debt (2016)
Krystal Biotech (KRYS) posted quarterly Convertible Debt of $1.1 million for Q4 2016.
Powered by 
Analysis
Krystal Biotech (KRYS) Convertible Debt (2016) Analysis & Trends
Krystal Biotech has reported Convertible Debt for 1 years, with the latest figure at $1.1 million in Q4 2016.
- Convertible Debt for Q4 2016 came in at $1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $1.1 million (changed N/A YoY), and the FY2016 annual result was $1.1 million, changed N/A from the prior year.
- Convertible Debt held at $1.1 million in Q4 2016.
- Over five years, Convertible Debt peaked at $1.1 million in Q4 2016 and troughed at $1.1 million in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Krystal Biotech | 10.61 Bn | 9.76 Bn | 112.79 Mn |